GSK plc
GSK
$46.63
-$0.47-1.00%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 128.01% | -13.09% | -29.53% | -46.81% | -57.52% |
| Total Depreciation and Amortization | 17.65% | 47.97% | 32.62% | 15.38% | 95.62% |
| Total Amortization of Deferred Charges | 7.16% | 7.16% | 7.16% | 7.16% | 5.24% |
| Total Other Non-Cash Items | 705.07% | 785,582.16% | 344.37% | 203.35% | -122.26% |
| Change in Net Operating Assets | -215.12% | -159.95% | -174.30% | 137.46% | 169.89% |
| Cash from Operations | 8.83% | 6.80% | -10.29% | -0.79% | 39.38% |
| Capital Expenditure | -1.41% | -1.18% | -4.15% | -9.37% | -9.67% |
| Sale of Property, Plant, and Equipment | 573.08% | 230.74% | 200.96% | 138.58% | -92.44% |
| Cash Acquisitions | -134.05% | -6.20% | 58.53% | 43.12% | 50.10% |
| Divestitures | -73.25% | -105.22% | -131.34% | -137.24% | -159.93% |
| Other Investing Activities | -165.01% | -159.13% | -101.46% | -15.45% | 853.91% |
| Cash from Investing | -3,618.95% | -1,043.99% | -69.43% | 19.54% | 105.55% |
| Total Debt Issued | 382.68% | 300.74% | 1,138.91% | 501.35% | -149.18% |
| Total Debt Repaid | -0.43% | -23.56% | 13.76% | 2.04% | 2.67% |
| Issuance of Common Stock | -33.33% | -25.00% | -36.36% | 66.67% | 90.91% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -8.63% | -8.80% | -11.71% | -11.75% | -6.56% |
| Other Financing Activities | -44.70% | -7.66% | -11.83% | -8.72% | 18.46% |
| Cash from Financing | 47.55% | 52.37% | 54.87% | 14.29% | -126.95% |
| Foreign Exchange rate Adjustments | 133.10% | -77.31% | 45.44% | 43.11% | -366.91% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2,699.00% | 352.82% | 1,343.70% | 202.46% | 104.40% |